A Phase 1, Open-label, First-in-human, Multi-center, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY 2315497 Injection, in Patients With Metastatic Castration Resistant Prostate Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2019
At a glance
- Drugs BAY 2315497 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 08 Jan 2019 Planned initiation date changed from 30 Nov 2018 to 31 Dec 2018.
- 29 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 30 Nov 2018.
- 08 Nov 2018 New trial record